Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.
- NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_assertion description "[HER-2/neu-overexpressing breast cancer cells are more resistant to the chemotherapeutic agent paclitaxel (Taxol) than low-HER-2/neu-expressing breast cancer cells, and the adenoviral type 5 EIA can down-regulate HER-2/neu overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.
- NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_assertion evidence source_evidence_literature NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.
- NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_assertion SIO_000772 10656456 NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.
- NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_assertion wasDerivedFrom befree-2016 NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.
- NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_assertion wasGeneratedBy ECO_0000203 NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.
- befree-2016 importedOn "2016-02-19" NP273917.RAKEz3rSoN_QXD3MmrYkfNv7sl3dYW9gEPOtRmZx40naU130_provenance.